Editing Psilocybin (section)

===Medical===
Psilocybin is approved by the [[Therapeutic Goods Administration]] (TGA) for treatment of [[treatment-resistant depression]] in [[Australia]] as of 2023.<ref name="Nutt_2024">{{cite journal | vauthors = Nutt DJ, Hunt P, Schlag AK, Fitzgerald P | title = The Australia story: Current status and future challenges for the clinical applications of psychedelics | journal = British Journal of Pharmacology | date = December 2024 | pmid = 39701143 | doi = 10.1111/bph.17398 }}</ref><ref name="Donley_2023">{{cite journal | vauthors = Donley CN, Dixon Ritchie G, Dixon Ritchie O | title = From prohibited to prescribed: The rescheduling of MDMA and psilocybin in Australia | journal = Drug Science, Policy and Law | volume = 9 | date = 2023 | doi = 10.1177/20503245231198472 | issn = 2050-3245 | doi-access = free | url = https://journals.sagepub.com/doi/pdf/10.1177/20503245231198472 | access-date = 17 May 2025 }}</ref><ref name="Zagorski_2023">{{cite journal | vauthors = Zagorski N | title = Australia Legalizes Psychedelics for Use in Depression, PTSD Therapy | journal = Psychiatric News | volume = 58 | issue = 09 | date = 1 September 2023 | doi = 10.1176/appi.pn.2023.09.9.20 | issn = 0033-2704 | url = https://psychiatryonline.org/doi/10.1176/appi.pn.2023.09.9.20 | access-date = 17 May 2025 }}</ref> It is also under development for the treatment of [[depression (mood)|depression]] and for various other indications elsewhere throughout the world, such as the [[United States]] and [[Europe]], but has not been approved in other countries at this time (see [[#Research|below]]).<ref name="DoddNormanEyre2023" /><ref name="MaddenFloodYoungShing2024" /><ref name="AdisInsight" />